Source: http://www.google.com/patents/US7700719?dq=mirroring+data+in+a+remote+data+storage+system
Timestamp: 2014-03-12 10:40:56
Document Index: 723456523

Matched Legal Cases: ['Application No. 05753672', 'Application No. 07747965', 'Application No. 01945896', 'Application No. 01945896', 'Application No. 01945896', 'Application No. 01945896', 'Application No. 01945896', 'Application No. 01945896']

Patent US7700719 - Arctic β amyloid protofibril - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsThe present invention relates to prevention and treatment of Alzheimer's disease (AD). More specifically, the invention relates to use of a non-wild type protofibril or compound(s) with protofibril forming activity for active immunisation in the purpose of treating or preventing AD. The invention further...http://www.google.com/patents/US7700719?utm_source=gb-gplus-sharePatent US7700719 - Arctic β amyloid protofibrilAdvanced Patent SearchPublication numberUS7700719 B2Publication typeGrantApplication numberUS 11/654,508Publication dateApr 20, 2010Filing dateJan 18, 2007Priority dateJul 7, 2000Fee statusPaidAlso published asCA2414772A1, CA2414772C, EP1309341A2, EP2082749A2, EP2082749A3, US7179463, US8409575, US20020162129, US20070248606, US20080181902, US20120027755, US20120156222, WO2002003911A2, WO2002003911A3, WO2002003911A8, WO2002003911B1Publication number11654508, 654508, US 7700719 B2, US 7700719B2, US-B2-7700719, US7700719 B2, US7700719B2InventorsLars Lannfelt, Camilla Nilsberth, Anita Campbell, Jan N�slundOriginal AssigneeBioarctic Neuroscience AbExport CitationBiBTeX, EndNote, RefManPatent Citations (75), Non-Patent Citations (260), Referenced by (2), Classifications (30), Legal Events (2) External Links: USPTO, USPTO Assignment, EspacenetArctic β amyloid protofibrilUS 7700719 B2Abstract The present invention relates to prevention and treatment of Alzheimer's disease (AD). More specifically, the invention relates to use of a non-wild type protofibril or compound(s) with protofibril forming activity for active immunisation in the purpose of treating or preventing AD. The invention further relates to a peptide, Aβ-Arc, with high protofibril forming activity as well as several applications thereof, such as antibodies against said peptide for passive immunisation against AD.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS5604102Oct 27, 1993Feb 18, 1997Athena Neurosciences, Inc.Methods of screening for β-amyloid peptide production inhibitorsUS5612486Nov 1, 1993Mar 18, 1997Athena Neurosciences, Inc.Transgenic animals harboring APP allele having swedish mutationUS5679531Jun 7, 1995Oct 21, 1997Bayer CorporationMethods of detecting βA4 peptide species ending at carboxy-terminus residue 42 using monoclonal antibody 369.2BUS5753624Aug 8, 1996May 19, 1998Milkhaus Laboratory, Inc.Materials and methods for treatment of plaquing diseaseUS5817626Mar 14, 1995Oct 6, 1998Praecis Pharmaceuticals IncorporatedModulators of beta-amyloid peptide aggregationUS5850003Jan 22, 1997Dec 15, 1998Athena NeurosciencesTransgenic rodents harboring APP allele having swedish mutationUS5851996Feb 13, 1998Dec 22, 1998Milkhaus Laboratory, Inc.Materials and methods for treatment of plaquing diseasesUS5854204Mar 14, 1996Dec 29, 1998Praecis Pharmaceuticals, Inc.Aβ peptides that modulate β-amyloid aggregationUS5854215Jun 7, 1995Dec 29, 1998Praecis Pharmaceuticals IncorporatedModulators of β-amyloid peptide aggregationUS5985242Aug 27, 1997Nov 16, 1999Praecis Pharmaceuticals, Inc.Modulators of β-amyloid peptide aggregation comprising D-amino acidsUS6054114May 7, 1997Apr 25, 2000Massachusetts Institute Of TechnologyOrganometallic ligands for the localization and quantification of amyloid in vivo and in vitroUS6114133 *Nov 14, 1994Sep 5, 2000Elan Pharmaceuticals, Inc.Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)US6174916Aug 8, 1997Jan 16, 2001Milkhaus Laboratory, Ltd.Methods for treating herpes virus infectionsUS6218506Feb 5, 1997Apr 17, 2001Northwestern UniversityAmyloid β protein (globular assembly and uses thereof)US6245964Dec 10, 1998Jun 12, 2001Elan Pharmaceuticals, Inc.Transgenic rodent comprising APP-SwedishUS6303567Aug 27, 1996Oct 16, 2001Praecis Pharmaceuticals, Inc .Modulators of β-amyloid peptide aggregation comprising D-amino acidsUS6319498Mar 14, 1996Nov 20, 2001Praecis Pharmaceuticals IncorporatedModulators of amyloid aggregationUS7179463Jul 9, 2001Feb 20, 2007Lars LannfeltTreatment of alzheimer's diseaseUS20020162129Jul 9, 2001Oct 31, 2002Lars LannfeltPrevention and treatment of alzheimer's diseaseUS20030068316Jun 11, 2002Apr 10, 2003Klein William L.Anti-ADDL antibodies and uses thereofUS20030187011Dec 17, 2002Oct 2, 2003Lashuel Hilal A.Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based diseaseUS20030232758Apr 10, 2003Dec 18, 2003Hospital For Sick Children And University Of TorontoImmunological methods and compositions for the treatment of Alzheimer's diseaseUS20040049134Jul 1, 2003Mar 11, 2004Tosaya Carol A.System and methods for treatment of alzheimer's and other deposition-related disorders of the brainUS20050124016Aug 2, 2004Jun 9, 2005Enh Research InstituteAntibodies specific for toxic amyloid beta protein oligomersUS20060079447Oct 7, 2005Apr 13, 2006Wetzel Ronald BStabilized A-beta protofibrillar aggregatesUS20060166275May 16, 2005Jul 27, 2006Northwestern University & University Of Southern CaliforniaAmyloid beta protein (globular assembly and uses thereof)US20060178302Apr 6, 2005Aug 10, 2006Northwestern University & The University Of Southern CaliforniaAmyloid beta protein (globular assembly and uses thereof)US20060193850Jan 27, 2006Aug 31, 2006Warne Nicholas WAnti a beta antibody formulationUS20060228349Oct 21, 2005Oct 12, 2006Paul ActonAnti-ADDL antibodies and uses thereofUS20060240486Dec 15, 2005Oct 26, 2006Johnson-Wood Kelly LImmunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodiesUS20060280733Sep 12, 2003Dec 14, 2006The Regents Of The University Of CaliforniaImmunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequenceUS20070048312Jul 31, 2006Mar 1, 2007Klein William LAnti-ADDL antibodies and uses thereofUS20070081998Oct 17, 2006Apr 12, 2007Gene KinneyAnti-ADDL monoclonal antibody and use thereofUS20070098721Feb 2, 2004May 3, 2007Heinz HillenAmyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereofUS20070099185Nov 4, 2003May 3, 2007Bioarctic Neuroscience AbMethods for the identification of agents that modulate the structure and processing of beta-amyloid precursor proteinUS20070110750Sep 13, 2004May 17, 2007The Regents Of The University Of CaliforniaMonoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequenceUS20070148167Oct 17, 2006Jun 28, 2007Strohl William RNon-immunostimulatory antibody and compositions containing the sameUS20080181902Mar 19, 2008Jul 31, 2008Lars LannfeltPrevention and treatment of alzheimer's diseaseEP0783104A1Dec 17, 1996Jul 9, 1997Oriental Yeast Co., Ltd.Method for assaying soluble amyloid precursor proteinWO1991016819A1Mar 26, 1991Oct 28, 1991Molecular Rx IncMethod and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta proteinWO1995011994A1Oct 17, 1994May 4, 1995Athena Neurosciences IncMethods of screening for beta-amyloid peptide production inhibitorsWO1995031996A1May 25, 1995Nov 30, 1995Milkhaus LabMaterials and methods for treatment of plaquing diseasesWO1997041856A1May 7, 1997Nov 13, 1997Brigham & Womens HospitalORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO)WO1998033815A1Feb 5, 1998Aug 6, 1998Acumen Pharmaceuticals IncAmyloid beta protein (globular assembly and uses thereof)WO1999027944A1Nov 30, 1998Jun 10, 1999Athena Neurosciences IncPrevention and treatment of amyloidogenic diseaseWO1999027949A1Dec 3, 1998Jun 10, 1999Brigham & Womens HospitalMETHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASEWO2000039310A1Dec 29, 1999Jul 6, 2000Nanda MenonRubredoxin fusion proteins, protein expression system and methodsWO2000071671A2May 26, 2000Nov 30, 2000Univ New YorkNew mutant genes in familial british dementia and familial danish dementiaWO2000072870A1Jun 1, 2000Dec 7, 2000Hirtzer PamelaCompositions of a-beta peptide and processes for producing sameWO2000072876A2Jun 1, 2000Dec 7, 2000Neuralab LtdPrevention and treatment of amyloidogenic diseaseWO2000072880A2May 26, 2000Dec 7, 2000Neuralab LtdPrevention and treatment of amyloidogenic diseaseWO2001010900A2Aug 4, 2000Feb 15, 2001Ann BarlowGlobular assembly of amyloid beta protein and uses thereofWO2001039796A2Nov 29, 2000Jun 7, 2001Chalifour RobertVaccine for the prevention and treatment of alzheimer's and amyloid related diseasesWO2001090182A2May 22, 2001Nov 29, 2001Blas FrangioneSynthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid depositsWO2002003911A2Jul 5, 2001Jan 17, 2002Lars LannfeltPrevention and treatment of alzheimer's diseaseWO2003089460A1Apr 7, 2003Oct 30, 2003Univ TorontoImmunological methods and compositions for the treatment of alzheimer's diseaseWO2003104437A2Jun 11, 2003Dec 18, 2003Lei ChangAnti-addl antibodies and uses thereofWO2004024090A2Sep 12, 2003Mar 25, 2004Charles G GlabeImmunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequenceWO2004031400A2Oct 1, 2003Apr 15, 2004Univ NorthwesternAmyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereofWO2005019828A1Aug 20, 2004Mar 3, 2005Neil CashmanEpitope protection assay and method for detecting protein conformationsWO2005025516A2Sep 13, 2004Mar 24, 2005Charles G GlabeMonoclonal antibodies specific for conformational epitopes of prefibrillar aggregatesWO2005089539A1Mar 17, 2005Sep 29, 2005Bioarctic Neuroscience AbTransgenic model for alzheimer�s diseaseWO2005123775A1Jun 21, 2005Dec 29, 2005Bioarctic Neuroscience AbAntibodies specific for soluble amyloid beta peptide protofibrils and uses thereofWO2006014478A1Jul 5, 2005Feb 9, 2006Univ NorthwesternMONOLOCAL ANTIBODIES THAT TARGET PATHOLOGICAL ASSEMBLIES OF AMYLOID β (ABETA)WO2006047254A1Oct 21, 2005May 4, 2006Univ MinnesotaAssemblies of oligomeric amyloid beta protein and uses thereofWO2006055178A2Oct 21, 2005May 26, 2006Merck & Co IncAnti-addl antibodies and uses thereofWO2006066233A1Dec 15, 2005Jun 22, 2006Neuralab LtdAn immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodiesWO2006083533A2Jan 17, 2006Aug 10, 2006Jeannie ChenCompositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disordersWO2006094724A2Mar 3, 2006Sep 14, 2006Abbott Gmbh & Co KgScreening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodiesWO2006137354A1Jun 19, 2006Dec 28, 2006Med & Biological Lab Co LtdAntibody having inhibitory effect on amyloid fibril formationWO2007005358A2Jun 26, 2006Jan 11, 2007Merck & Co IncMethod for preparing a covalently cross linked oligomer of amyloid beta peptidesWO2007005359A1Jun 26, 2006Jan 11, 2007Merck & Co IncComposition and method for producing stable amyloid beta oligomers of high molecular weightWO2007050359A2Oct 17, 2006May 3, 2007Merck & Co IncAnti-addl monoclonal antibody and use thereofWO2007062088A1Nov 21, 2006May 31, 2007Edward B LeeAntibody treatment of alzheimer's and related diseasesWO2007108756A1Mar 23, 2007Sep 27, 2007Bioarctic Neuroscience AbImproved protofibril selective antibodies and the use thereof* Cited by examinerNon-Patent CitationsReference1Advisory Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Feb. 20, 2004.2Andreasen and Blennow, "Beta-amyloid (Abeta) Protein in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease," Peptides 23:1205-1214, 2002.3Axelman et al., "A Large Swedish Family with Alzheimer's Disease with a Codon 670/671 Amyloid Precursor Protein Mutation," Arch. Neurol. 51:1193-1197, 1994.4Bacskai et al., "Imaging of Amyloid-β Deposits in Brains of Living Mice Permits Direct Observation of Clearance of Plaques with Immunotherapy," Nature Med. 7(3):369-372, 2001.5Bacskai, et al., Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy, Nature Medicine, 7(3):369-372 (Mar. 2001).6Bacskai, et al., Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy, Nature Medicine, 7(3):369-372 (Mar. 2001).7Bard et al., "Peripherally Administered Antibodies Against Amyloid β-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease," Nature Med. 6(8):916-919, 2000.8Bard, et al., Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nature Medicine, 6(8):916-919 (Aug. 2000).9Bard, et al., Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nature Medicine, 6(8):916-919 (Aug. 2000).10Barghorn et al., "Globular Amyloid β-Peptide Oligomer: A Homogenous and Stable Neuropathological Protein in Alzheimer's Disease," J. Neurochem. 95:834-47, 2005.11Bayer et al., "Evaluation of the Safety and Immunogenicity of Synthetic Aβ42 (AN1792) in Patients with AD," Neurology 64:94-101, 2005.12Bitan et al., "Amyloid β-Protein (Aβ) Assembly: Aβ40 and Aβ42 Oligomerize Through Distinct Pathways," Proc. Natl. Acad. Sci. U.S.A. 100:330-5, 2003.13Blanchard et al., "Efficient Reversal of Alzheimer's Disease Fibril Formation and Elimination of Neurotoxicity by a Small Molecule," Proc. Natl. Acad. Sci. U.S.A. 101(40):14326-32, 2004.14Cai et al., "Release of Excess Amyloid β-Protein from a Mutant Amyloid β-Protein Precursor," Science 259:514-516, 1993.15Caughey and Lansbury, "Protofibrils, Pores, Fibils, and Neurodegeneration: Separating the Responsible Protein Aggregates from the Innocent Bystanders," Ann. Rev. Neurosci. 26:267-98, 2003.16Chen et al., "A Learning Deficit Related to Age and β-Amyloid Plaques in a Mouse Model of Alzheimer's Disease," Nature 408:975-978, 2000.17Chen, et al., A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease, Nature, 408:975-978 (Dec. 2000).18Chen, et al., A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease, Nature, 408:975-978 (Dec. 2000).19Chromy et al., "Self-Assembly of Aβ1-42 Into Globular Neurotoxins," Biochemistry 42:12749-12760, 2003.20Chromy et al., "Stability of Small Oligomers of Aβ1-42 (ADDLs)," Society for Neuroscience 25:2129; 852.5, 1999.21Citron et al., "Mutant Presenilins of Alzheimer's Disease Increase Production of 42-Residue Amyloid β-Protein in Both Transfected Cells and Transgenic Mice," Nature Med. 3(1):67-72, 1997.22Citron et al., "Mutation of the (β-Amyloid Precursor Protein in Familial Alzheimer's Disease Increases β-Protein Production," Nature 360:672-674, 1992.23Citron, et al., Mutant presenilins of ALzheinmer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice, Nature Medicin, 3(1) 67-72 (Jan. 1997).24Citron, et al., Mutant presenilins of ALzheinmer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice, Nature Medicin, 3(1) 67-72 (Jan. 1997).25Communication from European Patent Application No. 05753672.4-2402, mailed Jul. 6, 2009.26Conway et al., "Acceleration of Oligomerization, Not Fibrillization, is a Shared Property of Both α-Synuclein Mutations Linked to Early-Onset Parkinson's Disease: Implications for Pathogenesis and Therapy," Proc. Natl. Acad. Sci. U.S.A. 97(2):571-576, 2000.27Conway, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson' disease: Implications for pathogenesis and therapy, PNAS, 97(2):571-576 (Jan. 18, 2000).28Conway, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson' disease: Implications for pathogenesis and therapy, PNAS, 97(2):571-576 (Jan. 18, 2000).29Dahlgren et al., "Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability," J. Biol. Chem. 277:32046-53, 2002.30Dalfo et al., "Evidence of Oxidative Stress in the Neocortex in Incidental Lewy Body Disease," J. Neuropathol. Exp. Neuro. 64(9):816-830, 2005.31De Jonghe et al., "Flemish and Dutch Mutations in Amyloid β Precursor Protein Have Different Effects on Amyloid β Secretion," Neurobiol. Dis. 5:281-286, 1998.32De Jonghe, et al., Flemish and Dutch Mutations in Amyloid beta Precursor Protein Hane Different Effects on Amyloid beta Secretion, Neurobiology of Disease, 5:281-286 (accepted for publ. Aug. 19, 1998.33De Jonghe, et al., Flemish and Dutch Mutations in Amyloid β Precursor Protein Hane Different Effects on Amyloid β Secretion, Neurobiology of Disease, 5:281-286 (accepted for publ. Aug. 19, 1998.34Declaration Under Rule 132 (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Mar. 9, 2006.35DeMarco et al., "From Conversion to Aggregation: Protofibril Formation of the Prion Protein," Proc. Natl. Acad. Sci. U.S.A. 101:2293-2298, 2004.36Dodart et al., "Immunization Reverses Memory Deficits Without Reducing Brain Aβ Burden in Alzheimer's Disease Model," Nature Neurosci. 5:452-457, 2002.37El-Agnaf et al., "Oligomerization and Toxicity of β-Amyloid-42 Implicated in Alzheimer's Disease," Biochem. Biophys. Res. Comm. 273:1003-1007, 2000.38Enya et al., "Appearance of Sodium Dodecyl Sulfate-Stable Amyloid β-Protein (Aβ) Dimer in the Cortex During Aging," Am. J. Pathol. 154:271-279, 1999.39European Examination Report (EP 01 945 896.7), dated Apr. 24, 2007.40European Examination Report (EP 01 945 896.7), dated May 22, 2006.41European Examination Report (EP 01 945 896.7), dated Sep. 30, 2005.42Extended European Search Report from European Patent Application No. 07747965.7, dated May 13, 2009.43Finder and Glockshuber, "Amyloid-β Aggregation," Neurodegener. Dis. 4(1):13-27, 2007.44Forsell et al., "Amyloid Precursor Protein Mutation at Codon 713 (Ala ->Val) Does Not Cause Schizophrenia: Non-Pathogenic Variant Found at Codon (Silent)," Neurosci. Lett. 184:90-93, 1995.45Forsell et al., "Amyloid Precursor Protein Mutation at Codon 713 (Ala →Val) Does Not Cause Schizophrenia: Non-Pathogenic Variant Found at Codon (Silent)," Neurosci. Lett. 184:90-93, 1995.46Forsell, et al., Amyloid precursor protein mutation at codon 713(Ala-Val) does not cause schizophrenia: non-pathogenic variant found at codon 705 (silent) , Newroscience Letters, 184:90-93 (accepted Nov. 18, 1994).47Frackowiak et al., "Non-Fibrillar β-Amyloid Protein is Associated with Smooth Muscle Cells of Vessel Walls in Alzheimer Disease," J. Neuropathol. Exp. Neurol. 53:637-645, 1994.48Frenkel et al, "Modulation of Alzheimer's Beta-amyloid Neurotoxicity by Site-directed Single-chain Antibody," J. Neuroimmunol. 106:23-31, 2000.49Frenkel et al, "Modulation of Alzheimer's Beta-amyloid Neurotoxicity by Site-directed Single-chain Antibody," Neuroimmunomodulation 6:444, 1999.50Frenkel et al., "Immunization Against Alzheimer's β-Amyloid Plaques Via EFRH Phage Administration," Proc. Natl. Acad. Sci. U.S.A. 97(21):11455-11459, 2000.51Frenkel, et al., Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration, PNAS, 97(21):11455-11459 (Oct. 10, 2000).52Frenkel, et al., Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration, PNAS, 97(21):11455-11459 (Oct. 10, 2000).53Giulian et al., "The HHQK Domain of β-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," J. Biol. Chem. 273(45):29719-29726, 1998.54Giulian, et al., The HHQK Domain of beta-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease, The Journal of Biological Chemistry, 273(45):29719-29726 (Nov. 6, 1998).55Giulian, et al., The HHQK Domain of β-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease, The Journal of Biological Chemistry, 273(45):29719-29726 (Nov. 6, 1998).56Glenner et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," Biochem. Biophys. Res. Comm. 120(3):885-890, 1984.57Grabowski et al., "Novel Amyloid Precursor Protein Mutation in an Iowa Family with Dementia and Severe Cerebral Amyloid Angiopathy," Ann. Neuro. 49:697-705, 2001.58Grabowski, et al., Novel Amyloid Precursor Protein Mutation in an Iowa Family with Dementia and Severe Cerebral Amyloid Angiopathy, Ann. Neurol., 49:697-705 (published online Mar. 19, 2001).59Guerette et al., "Oligomeric Aβ in PBS-Soluble Extracts of Human Alzheimer Brain," Society for Neuroscience 25:2129; 852.1, 1999.60Hardy, "Amyloid, the Presenilins and Alzheimer's Disease," Trends Neurosci. 20(4):154-159, 1997.61Hardy, "Framing β-Amyloid," Nature Genet. 1:233-234, 1992.62Hardy, Amyloid, the presenillins and Alzheimer's disease, Trends Neurosci., 20(4):154-159 (1997).63Harper et al., "Assembly of Aβ Amyloid Protofibrils: An In Vitro Model for a Possible Early Event in Alzheimer's Disease," Biochemistry 38:8972-8980, 1999.64Harper et al., "Observation of Metastable Aβ Amyloid Protofibrils by Atomic Force Microscopy," Chem. Biol. 4:119-125, 1997.65Harper, et al., Assembly of Abeta Amyloid Protofibrils: An in Vitro Model for aPossible Early Event in Alzheimer's Disease, Biochemistry, 38:8972-8980 (published online Jun. 18, 1999).66Harper, et al., Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for aPossible Early Event in Alzheimer's Disease, Biochemistry, 38:8972-8980 (published online Jun. 18, 1999).67Hartley et al., "Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons," J. Neurosci. 19(20):8876-8884, 1999.68Hendriks et al., "Presenile Dementia and Cerebral Hemorrhage Linked to a Mutation at Codon 692 of the β- Amyloid Precursor Protein Gene," Nature Genet. 1:218-221, 1992.69Hendriks, et al., Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene, Nature Genetics, 1:218-221 (Jun. 1992).70Hendriks, et al., Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene, Nature Genetics, 1:218-221 (Jun. 1992).71Hock and Nitsch, "Clinical Observations with AN-1792 Using TAPIR Analyses," Neurodegener Dis. 2:273-276, 2005.72Hoshi et al., "Spherical Aggregates of β-Amyloid (Amylospheroid) Show High Neurotoxicity and Activate Tau Protein Kinase I/glycogen Synthase Kinase-3β," Proc. Natl. Acad. Sci. U.S.A. 100(11):6370-6375, 2003.73International Preliminary Report (PCT/US2003/30930), completed Feb. 6, 2006.74International Preliminary Report on Patentability (PCT/SE01/01553), completed Oct. 23, 2002.75International Preliminary Report on Patentability (PCT/SE05/000993), issued Dec. 28, 2006.76International Preliminary Report on Patentability (PCT/SE07/000292), issued Sep. 23, 2008.77International Preliminary Report on Patentability (PCT/US2003/19640), completed Aug. 7, 2006.78International Search Report (PCT/SE01/01553), mailed Feb. 4, 2002.79International Search Report (PCT/SE05/000993), mailed Oct. 4, 2005.80International Search Report (PCT/SE07/000292), mailed Jul. 20, 2007.81Interview Summary (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), dated Oct. 21, 2003.82Isaacs et al., "Acceleration of Amyloid β-Peptide Aggregation by Physiological Concentrations of Calcium," J. Biol. Chem. 281(38):27916-23, 2006.83Janus et al., "A β Peptide Immunization Reduces Behavioral Impairment and Plaques in a Model of Alzheimer's Disease," Nature 408:979-982, 2000.84Janus, et al., Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, 408:979-982 (Dec. 2000).85Janus, et al., Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, 408:979-982 (Dec. 2000).86Jensen et al., "Quantification of Alzheimer Amyloid beta Peptides Ending at Residues 40 and 42 by Novel ELISA Systems," Mol. Med. 6:291-302, 2000.87Jensen et al., "Quantification of Alzheimer Amyloid β Peptides Ending at Residues 40 and 42 by Novel ELISA Systems," Mol. Med. 6:291-302, 2000.88Johansson et al., "Physiochemical Characterization of the Alzheimer's Disease-Related Peptides Abeta1-42 Arctic and Abeta1-42 wt" FEBS J. 273:2618-2630, 2006.89Johansson et al., "Physiochemical Characterization of the Alzheimer's Disease-Related Peptides Aβ1-42 Arctic and Aβ1-42 wt" FEBS J. 273:2618-2630, 2006.90Johnston et al., "Increased beta-Amyloid Release and Levels of Amyloid Precursor Protein (APP) in Fibroblast Cell Lines From Family Members With the Swedish Alzheimer's Disease APP670/671 Mutation," FEBS Lett. 354:274-278, 1994.91Johnston et al., "Increased β-Amyloid Release and Levels of Amyloid Precursor Protein (APP) in Fibroblast Cell Lines From Family Members With the Swedish Alzheimer's Disease APP670/671 Mutation," FEBS Lett. 354:274-278, 1994.92Kamino et al., "Linkage and Mutational Analysis of Familial Alzheimer Disease Kindreds for the APP Gene Region," Am. J. Hum. Genet. 51:998-1014, 1992.93Kamino, et al., Linkage and Mutational Analysis of Familial Alzheimer Disease Kindreds for the APP Gene Regin, Am. J. Hum. Genet. 51:998-1014 (revision reveived Jul. 24, 1992.94Kang et al., "The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-surface Receptor," Nature 325:733-736, 1987.95Kayed et al., "Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis," Science 300:486-489, 2003.96Kayed et al., "Immunization With a Molecular Mimic of a Toxic Aggregates Generates a Conformation-Dependent Antibody Specific for High Molecular Weight A Aggregates (Micelles and Protofibrils)," 32nd Annual Meeting of the Society for Neuroscience, Orlando, Florida (Society for Neuroscience Abstract Viewer and Itinerary Planner, Abstract No. 685.3, 2002).97Kirkitadze et al., "Paradigm Shifts in Alzheimer's Disease and Other Neurodegenerative Disorders:The Emerging Role of Oligomeric Assemblies," J. Neurosci. Res. 1, 69:567-77, 2002.98Klafki et al., "Therapeutic Approaches to Alzheimer's Disease," Brain 129:2840-2855, 2006.99Klein et al., "Oligemia-Induced Expression of c-fos and Oxidative Stress-Related Protein in the Murine Brain," 30th Annual Meeting of the Society of Neuroscience, New Orleans, LA, Nov. 4-9, 2000, Soc. Neurosci. Abstracts 26(1-2), Abstract 383.15, 2000.100Klein et al., "Oligomer/Conformation-Dependent Aβ Antibodies," Soc. Neurosci. Abstr. Presentation No. 475.11, Tuesday Nov. 7, 2000.101Klein et al., "Targeting Small Aβ Oligomers: The Solution to an Alzheimer's Disease Conundrum?" Trends Neurosci. 24:219-224, 2001.102Klein, "Aβ Toxicity in Alzheimer's Disease," Contemporary Clinical Neuroscience: Molecular Mechanisms of Neurodegenerative Diseases 1.1 Introduction, 2001.103Klyubin et al., "Inhibitory Effect of Amyloid-β Peptide with the Arctic Mutation on Long-term Potentiation in Area CA1 of Rat Hippocampus In Vivo," J. Physio., 551P, C32, 2003.104Klyubin et al., "Soluble Arctic Amyloid β Protein Inhibits Hippocampal Long-Term Potentiation In Vivo," Eur. J. Neurosci. 19:2839-2846, 2004.105Kuo et al., "Water-soluble Aβ (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," J. Biol. Chem. 271:4077-4081, 1996.106Lambert et al., "Diffusible, Nonfibrillar Ligands Derived From Aβ1-42 Are Potent Central Nervous System Neurotoxins," Proc. Natl. Acad. Sci. U.S.A. 95:6448-6453, 1998.107Lambert et al., "Monoclonal Antibodies that Target Pathological Assemblies of Aβ," J. Neurochem. 100:23-35, 2007.108Lambert et al., "Neuron Dysfunction and Death Caused by Small Aβ Oligomers: Role of Signal Transduction," Society for Neuroscience 25:2129, 1999.109Lambert et al., "Vaccination With Soluble Aβ Oligomers Generates Toxicity-Neutralizing Antibodies," J. Neurochem. 79:595-605, 2001.110Lannfelt et al., "Amyloid beta-Peptide in Cerebrospinal Fluid in Individuals with the Swedish Alzheimer Amyloid Precursor Protein Mutation," Neurosci. Lett. 199:203-206, 1995.111Lannfelt et al., "Amyloid Precursor Protein Mutation Causes Alzheimer's Disease in a Swedish Family," Neurosci. Lett. 168:254-256, 1994.112Lannfelt et al., "Genetics of Alzheimer's Disease-Routes to the Pathophysiology," J. Neural. Transm. [Suppl.] 59:155-161, 2000.113Lannfelt et al., "Genetics, Pathophysiology and Abeta Protofibril Formation in Alzheimer's Disease," Neurobiol. Aging 25(Suppl. 2): Poster Session P2: Epidemiology and Risk Factors of Alzheimer's Disease P2-268; S308, 2004.114Lannfelt et al., "Monoclonal Antibodies Selective for Abeta Protofibrils Reduce Plaque Sensitive Detection of Alzheimer Abeta Protofibrils by Burden in Transgenic Mice Models of Alzheimer's Disease Conformation Specific ELISA," ICAD meeting, Uppsala University, Sweden, Jul. 16, 2006.115Lannfelt et al., "Monoclonal Antibodies Selective for Abeta Protofibrils: Detection of Protofibrils and Reduction of Plaque Burden in Tg-mice Models of Alzheimer's Disease," SfN meeting, Uppsala University, Sweden, Oct. 17, 2006.116Lannfelt et al., "Amyloid β-Peptide in Cerebrospinal Fluid in Individuals with the Swedish Alzheimer Amyloid Precursor Protein Mutation," Neurosci. Lett. 199:203-206, 1995.117Lannfelt et al., "Genetics of Alzheimer's Disease�Routes to the Pathophysiology," J. Neural. Transm. [Suppl.] 59:155-161, 2000.118Lannfelt et al., "Genetics, Pathophysiology and Aβ Protofibril Formation in Alzheimer's Disease," Neurobiol. Aging 25(Suppl. 2): Poster Session P2: Epidemiology and Risk Factors of Alzheimer's Disease P2-268; S308, 2004.119Lannfelt et al., "Monoclonal Antibodies Selective for Aβ Protofibrils Reduce Plaque Sensitive Detection of Alzheimer Aβ Protofibrils by Burden in Transgenic Mice Models of Alzheimer's Disease Conformation Specific ELISA," ICAD meeting, Uppsala University, Sweden, Jul. 16, 2006.120Lannfelt et al., "Monoclonal Antibodies Selective for Aβ Protofibrils: Detection of Protofibrils and Reduction of Plaque Burden in Tg-mice Models of Alzheimer's Disease," SfN meeting, Uppsala University, Sweden, Oct. 17, 2006.121Lashuel et al., "Mixtures of Wild-Type and a Pathogenic (E22G) Form of Aβ40 In Vitro Accumulate Protofibrils, Including Amyloid Pores," J. Mol. Biol. 332:795-808, 2003.122Lee et al., "Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice," J. Biol. Chem. 2006 281:4292-4299.123Levy et al., "Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type," Science 248:1124-1126, 1990.124Levy, et al., Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type, Science, 248:1124-1126 (Jun. 1, 1990).125Liu et al., "Residues 17-20 and 30-35 of β-Amyloid Play Critical Roles in Aggregation," J. Neurosci. Res. 75(2):162-71, 2004.126Longo and Finch, "Nonfibrillar Aβ 1-42 (ADDL) Causes Aconitase Inactivation and Iron-dependent Neurotoxicity," Society for Neuroscience 25: 2129, 1999.127Masters et al., "Amyloid Plaque Core Protein in Alzheimer's Disease and Down Syndrome," Proc. Natl. Acad. Sci. U.S.A. 82:4245-4249, 1985.128McKhann et al., "Clinical Diagnosis of Alzheimer's Disease: Report of the NINCHS-ADRDA Work Group Under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease," Neurology 34:939-944, 1994.129Minutes from Oral Proceedings for European Patent Application No. 01945896.7-2402, dated Dec. 17, 2008.130Miravelle et al., "Substitutions at Codon 22 of Alzheimer's Aβ Peptide Induce Diverse Conformational Changes and Apoptotic Effects in Human Cerebral Endothelial Cells," J. Biol. Chem. 275:27110-27116, 2000.131Morgan et al., "Aβ Peptide Vaccination Prevents Memory Loss in an Animal Model of Alzheimer's Disease," Nature 408:982-985, 2000.132Morgan, et al., Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 408:982-985 (Dec. 2000).133Morgan, et al., Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 408:982-985 (Dec. 2000).134Moss et al., "The Peptide KLVFF-K6 Promotes β-Amyloid(1-40) Protofibril Growth by Association but Does Not Alter Protofibril Effects on Cellular Reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT)," Mol . Pharmacol. 64(5):1160-8, 2003.135Motter et al., "Reduction of β-Amyloid Peptide42 in the Cerebrospinal Fluid of Patients with Alzheimer's Disease," Ann. Neurol. 38:643-648, 1995.136Mullan et al., "A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-terminus of beta-Amyloid," Nature Genet. 1:345-347, 1992.137Mullan et al., "A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-terminus of β-Amyloid," Nature Genet. 1:345-347, 1992.138Mullan, et al., A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid, Natue Genetics, 1:345-347 (Aug. 1992).139Mullan, et al., A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid, Natue Genetics, 1:345-347 (Aug. 1992).140Nichols et al., "Amyloid-β Aggregates Formed at Polar-Nonpolar Interfaces Differ From Amyloid-β Protofibrils Produced in Aqueous Buffers," Microsc. Res. Tech. 67(3-4):164-74, 2005.141Nicoll et al., "Neuropathology of Human Alzheimer Disease After Immunization With Amyloid-β Peptide: A Case Report," Nature Med. 9(4):448-452, 2003.142Nilsberth et al., "A Novel APP Mutation (E693G)-The Arctic Mutation, Causing, Alzheimer's Disease with Vascular Symptoms," Society for Neuroscience Annual Meeting, Miami Beach, Abstract, 120.4; Nov. 1999.143Nilsberth et al., "The 'Arctic' APP Mutation (E693G) Causes Alzheimer's Disease by Enhanced Abeta Protofibril Formation," Nature Neurosci. 4(9):887-893, 2001.144Nilsberth et al., "The 'Arctic' APP Mutation (E693G) Causes Alzheimer's Disease by Enhanced Abeta Protofibril Formation," Neurobiology of Aging, May-Jun. 2000, 21, Abstract 265, Supplement 1, 1-304.145Nilsberth et al., "The Artic APP Mutation (E693G) Causes Alzheimer's Disease Through a Novel Mechanism: Increased Amyloid beta Protofibril Formation and Decreased Amyloid beta Levels in Plasma and Conditioned Media," Neurobiol. Aging 21:S58, 2000.146Nilsberth et al., "A Novel APP Mutation (E693G)�The Arctic Mutation, Causing, Alzheimer's Disease with Vascular Symptoms," Society for Neuroscience Annual Meeting, Miami Beach, Abstract, 120.4; Nov. 1999.147Nilsberth et al., "The �Arctic� APP Mutation (E693G) Causes Alzheimer's Disease by Enhanced Aβ Protofibril Formation," Nature Neurosci. 4(9):887-893, 2001.148Nilsberth et al., "The �Arctic� APP Mutation (E693G) Causes Alzheimer's Disease by Enhanced Aβ Protofibril Formation," Neurobiology of Aging, May-Jun. 2000, 21, Abstract 265, Supplement 1, 1-304.149Nilsberth et al., "The Artic APP Mutation (E693G) Causes Alzheimer's Disease Through a Novel Mechanism: Increased Amyloid β Protofibril Formation and Decreased Amyloid β Levels in Plasma and Conditioned Media," Neurobiol. Aging 21:S58, 2000.150Notice of Allowance (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Oct. 16, 2006.151Notice of Appeal (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Nov. 25, 2003.152Notice of intent to grant a European patent and Annex (Reasons for Decision) (EP 01 945 896.7), dated Mar. 18, 2009.153Notice of Non-Compliant Amendment (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed May 12, 2005.154Oda et al., "Clusterin (apoJ) Alters the Aggregation of Amyloidβ-Peptide (Aβ 1-42) and Forms Slowly Sedimenting Aβ Complexes that Cause Oxidative Stress," Exp. Neurol. 136:22-31, 1995.155Oda et al., "Purification and Characterization of Brain Clusterin," Biochem. Biophys. Res. Comm. 204:1131-6, 1994.156Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463) mailed May 8, 2006.157Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Jul. 7, 2005.158Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Jun. 25, 2003.159Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Nov. 19, 2002.160Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Nov. 24, 2004.161Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Nov. 9, 2005.162O'Nuallain et al., "Conformational Abs Recognizes a Generic Amyloid Fibril Epitope," Proc. Natl. Acad. Sci. U.S.A. 99:1485-1490, 2002.163P�ivi� et al., "Unique Physicochemical Profile of beta-Amyloid Peptide Variant Abeta 1-40E22G Protofibrils: Conceivable Neuropathogen in Arctic Mutant Carriers," J. Med. Biol. 339:145-159, 2004.164P�ivi� et al., "Unique Physicochemical Profile of β-Amyloid Peptide Variant Aβ 1-40E22G Protofibrils: Conceivable Neuropathogen in Arctic Mutant Carriers," J. Med. Biol. 339:145-159, 2004.165Palmert et al., "The β-Amyloid Protein Precursor of Alzheimer Disease Has Soluble Derivatives Found in Human Brain and Cerebrospinal Fluid," Proc. Natl. Acad. Sci. U.S.A. 86:6338-6342, 1989.166Palmert, et al., The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid, Proc. Natl. Acad. Sci. USA, 86:6338-6342 (Aug. 1989).167Palmert, et al., The β-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid, Proc. Natl. Acad. Sci. USA, 86:6338-6342 (Aug. 1989).168Pirttil� et al., "Soluble Amyloid β-Protein in the Cerebrospinal Fluid From Patients with Alzheimer's Disease, Vascular Dementia and Controls," J. Neurol. Sc. 127:90-95, 1994.169Ponte et al., "A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors," Nature 331:525-527, 1988.170Qin et al., "Effect of 4-Hydroxy-2-Nonenal Modification on Alpha-Synuclein Aggregation," J. Biol. Chem. 282(8):5862-5870, 2007.171Reply to Examination Report (European Patent Application No. 01945896.7-2402), mailed Apr. 7, 2006.172Reply to Examination Report (European Patent Application No. 01945896.7-2402), mailed Nov. 5, 2007.173Reply to Examination Report (European Patent Application No. 01945896.7-2402), mailed Sep. 22, 2006.174Reply to Notice of Non-Compliant Amendment (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed May 27, 2005.175Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Apr. 21, 2003.176Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Aug. 8, 2006.177Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Dec. 18, 2003.178Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Mar. 24, 2005.179Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Mar. 9, 2006.180Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Oct. 7, 2005.181Reply to Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Sep. 10, 2004.182Reply to Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Sep. 3, 2002.183Request For Continued Examination (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Mar. 25, 2004.184Request Pursuant to Oral Proceedings (European Patent Application No. 01945896.7-2402), mailed Oct. 10, 2008.185Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Jul. 3, 2002.186Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Jun. 10, 2004.187Resubmission of Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Feb. 3, 2004.188Roher et al., "Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease," J. Biol. Chem. 271:20631-20635, 1996.189Russo et al., "Presenilin-1 Mutations in Alzheimer's Disease," Nature 405:531-532, 2000.190Rzepecki et al., "Prevention of Alzheimer's Disease-Associated Aβ Aggregation by Rationally Designed Nonpeptitdic β-Sheet Ligands," J. Biol. Chem. 279:47497-47505, 2004.191Sahlin et al., "The Arctic Alzheimer Mutation Favors Intracellular Amyloid-beta Production by Making Amyloid Precursor Protein Less Available to alpha -secretase," J. Neurochem. 101:854-862, 2007.192Sahlin et al., "The Arctic Alzheimer Mutation Favors Intracellular Amyloid-β Production by Making Amyloid Precursor Protein Less Available to α -secretase," J. Neurochem. 101:854-862, 2007.193Schenk et al., "Immunization with Amyloid-β Attenuates Alzheimer-Disease-Like Pathology in the PDAPP," Nature 400:173-177, 1999.194Schenk, et al., Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP, Letters to Nature, 400:173-177 (Jul. 8, 1999).195Schenk, et al., Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP, Letters to Nature, 400:173-177 (Jul. 8, 1999).196Scheuner et al., "Secreted Amyloid beta-Protein Similar to That in the Senile Plaques of Alzheimer's Disease is Increased In Vivo by the Presenilin 1 and 2 and APP Mutations Linked to Familial Alzheimer's Disease." Nature Med. 2(8):864-870, 1996.197Scheuner et al., "Secreted Amyloid β-Protein Similar to That in the Senile Plaques of Alzheimer's Disease is Increased In Vivo by the Presenilin 1 and 2 and APP Mutations Linked to Familial Alzheimer's Disease." Nature Med. 2(8):864-870, 1996.198Scheuner, et al., Secreted amyloid beta-protein similar to that in thesenile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Nature Medicine, 2(8):864-870 (Aug. 1996).199Scheuner, et al., Secreted amyloid β-protein similar to that in thesenile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Nature Medicine, 2(8):864-870 (Aug. 1996).200Selkoe, "Cell Biology of the Amyloid β-Protein Precursor and the Mechanism of Alzheimer's Disease," Ann. Rev. Cell Biol. 10:373-403, 1994.201Selkoe, "Normal and Abnormal Biology of the β-Amyloid Precursor Protein," Ann. Rev. Neurosci. 17:489-517, 1994.202Serpell, "Alzheimer's Amyloid Fibrils: Structure and Assembly," Biochim. Biophys. Acta 1502:16-30, 2000.203Serpell, Alzheimer's amyloid fibrils: structure and assembly, Biochimica et Biophysica Acta, 1502:16-30 (accepted Nov. 24, 1999).204Seubert et al., "Isolation and Quantification of Soluble Alzheimer's β-Peptide From Biological Fluids," Nature 359:325-327, 1992.205Sherrington et al., "Cloning of a Gene Bearing Missense Mutations in Early-Onset Familial Alzheimer's Disease," Nature 375:754-760, 1995.206Sherrington et al., Cloning of agene bearing missense mutations in early-onset familial Alzheimer's disease, Nature, 375:754-760 (Jun. 29, 1995).207Shtilerman et al., "Molecular Crowding Accelerates Fibrillization of α-Synuclein: Could an Increase in the Cytoplasmic Protein Concentration Induce Parkinson's Disease?" Biochemistry 41:3855-3860, 2002.208Sigurdsson et al., "Immunization With a Nontoxic/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice," Am. J. Pathol. 159(2):439-447, 2001.209Solomon et al., "Disaggregation of Alzheimer β-amyloid by Site-directed mAb," Proc. Natl. Acad. Sci. U.S.A. 94:4109-4112, 1997.210Solomon et al., "Monoclonal Antibodies Inhibit In Vitro Fibrillar Aggregation of the Alzheimer Beta-amyloid Peptide," Proc. Natl. Acad. Sci. U.S.A. 93:452-455, 1996.211Solomon et al., "Monoclonal Antibodies Restore and Maintain the Soluble Conformation of β-amyloid Peptide," Neurobiol. Aging, vol. 17, No. 4, Suppl. 152, 1996.212Soto et al., "The Conformation of Alzheimer's β Peptide Determines the Rate of Amyloid Formation and Its Resistance to Proteolysis," Biochem. J. 1:314:701-7, 1996.213Srinivasan et al., "ABri Peptide Associated with Familial British Dementia Forms Annular and Ring-Like Protofibrillar Structures," Amyloid 11(1):10-3, 2004.214St. George-Hyslop et al., "Genetic Linkage Studies Suggest that Alzheimer's Disease is Not a Single Homogeneous Disorder," Nature 347:194-197, 1990.215St. George-Hyslop et al., "The Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21," Science 235:885-890, 1987.216St. George-Hyslop, et al., Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder, Letters to Nature, 347:194-197 (Sep. 13, 1990).217St. George-Hyslop, et al., The Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21, Science, 235:885-890( Feb. 20, 1987).218Stenh et al., "Amyloid-beta Oligomers are Inefficiently Measured by Enzyme-Linked Immunosorbent Assay," Ann. Neurol. 58: 147-150, 2005.219Stenh et al., "The Arctic Mutation Interferes with Processing of the Amyloid Precursor Protein," NeuroReport 13: 1857, 2002.220Stenh et al., "Amyloid-β Oligomers are Inefficiently Measured by Enzyme-Linked Immunosorbent Assay," Ann. Neurol. 58: 147-150, 2005.221Stine et al., "Supramolecular Structures of Aβ Aggregates and Cellular Responses," Biophysical Journal Program and Abstracts:40th Annual Meeting Feb. 17-21, 1996, Biophys J. 70: Abstract 239.222Stine et al., "The Nanometer-Scale Structure of Amyloid-β Visualized by Atomic Force Microscopy," J. Prot. Chem. 15(2):193-203, 1996.223Summons to Attend Oral Proceedings (European Patent Application No. 01945896.7-2402), dated Jul. 25, 2008.224Supplemental Reply to Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Sep. 21, 2004.225Suzuki et al., "An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βAPP717) Mutants," Science 264:1336-1340, 1994.226Suzuki, et al., An Increase Percentage of Long Amyloid beta Protein Secreted by Familial Amyloid beta Protein Precursor (betaAPP717) Mutants, Science, 264:1336-1340 (May 27, 1994).227Suzuki, et al., An Increase Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βAPP717) Mutants, Science, 264:1336-1340 (May 27, 1994).228Tagliavani et al., "A New βAPP Mutation Related to Hereditary Cerebral Haemorrhage," Alz. Report 2(Suppl. 1):S28, Abstract 23, 1999.229U.S. Appl. No. 09/369,236, filed Aug. 4, 1999, Krafft et al.230U.S. Appl. No. 09/745,057, filed Dec. 20, 2000, Krafft et al.231U.S. Appl. No. 10/166,856, filed Jun. 11, 2002, Klein et al.232U.S. Appl. No. 11/570,995, filed Dec. 20, 2006, Gellerfors et al.233U.S. Appl. No. 12/294,207, filed Sep. 23, 2008, Gellerfors et al.234U.S. Appl. No. 60/217,098, filed Jul. 10, 2000, Lannfelt et al.235U.S. Appl. No. 60/621,776, filed Oct. 25, 2004, Lambert et al.236U.S. Appl. No. 60/652,538, filed Feb. 14, 2005, Shughrue et al.237Vickers, "A Vaccine Against Alzheimer's Disease: Developments to Date," Drugs Aging 19(7):487-494, 2002.238Vickers, 2002, Drugs Aging, 19(7), pp. 487-494.239Walsh et al., "Amyloid β-Protein Fibrillogenesis. Detection of a Protofibrillar Intermediate," J. Biol. Chem. 272:22364-22372, 1997.240Walsh et al., "Amyloid β-Protein Fibrillogenesis. Structure and Biological Activity of Protofibrillar Intermediates," J. Biol. Chem. 274(35):25945-25952, 1999.241Walsh et al., "Amyloid-β Oligomers: Their Production, Toxicity and Therapeutic Inhibition," Biochem. Soc. Trans. 30:552-7, 2002.242Walsh et al., "Naturally Secreted Oligomers of Amyloid β Protein Potently Inhibit Hippocampal Long-Term Potentiation In Vivo," Nature 416:535-539, 2002.243Walsh et al., "Oligomers on the Brain: The Emerging Role of Soluble Protein Aggregates in Neurodegeneration," Protein Pept. Lett., 11: 213-28, 2004.244Walsh, et al., Amyloid beta-Protein Fibrillogenesis, the Journal of Biological Chemistry, 272(35):22364-22372 (Aug. 29, 1997).245Walsh, et al., Amyloid β-Protein Fibrillogenesis, the Journal of Biological Chemistry, 272(35):22364-22372 (Aug. 29, 1997).246Ward et al., "Fractionation and Characterization of Oligomeric, Protofibrillar Forms of β-Amyloid Peptide," Biochem. J. 348:137-144, 2000.247Weidemann et al., "Identification, Biogenesis, and Localization of Precursors of Alzheimer's Disease A4 Amyloid Protein," Cell 57:115-126, 1989.248Weidemann, et al., Identification, Biogenesis, and Localization of Precursors of Alzheimer's Disease A4 Amyloid Protein, Cell 57:115-126 (Apr. 7, 1989).249Weiner et al., "Nasal Administration of Amyloid-β Peptide Decreases Cerebral Amyloid Burden in a Mouse Model of Alzheimer's Disease," Annals Neurol. 48(4):567-579, 2000.250Westlind-Danielsson and Arnerup, "Spontaneous In Vitro Formation of Supramolecular β-Amyloid Structures, "βamy Balls", by β-Amyloid 1-40 peptide," Biochemistry 40:14736-43, 2001.251Williams et al., "Structural Properties of Aβ Protofibrils Stabilized by a Small Molecule," Proc. Natl. Acad. Sci. U.S.A. 102(20):7115-20, 2005.252Wirak et al., "Deposits of Amyloid β Protein in the Central Nervous System of Transgenic Mice," Science 253:323-325, 1991.253Wirak, et al., Deposits of Amyloid beta Protein in the Central Nervous System of Transgenic Mice, Science, 253:323-325 (Jul. 19, 1991).254Wirak, et al., Deposits of Amyloid β Protein in the Central Nervous System of Transgenic Mice, Science, 253:323-325 (Jul. 19, 1991).255WO 05/123775 A1, pp. 7-8, published Dec. 29, 2005.256Written Opinion of the International Searching Authority (PCT/SE05/000993), mailed Oct. 4, 2005.257Written Opinion of the International Searching Authority (PCT/SE07/000292), mailed Jul. 20, 2007.258Ye et al., "Protofibrils of Amyloid β-Protein Inhibit Specific K+ Currents in Neocortical Cultures," Neurobiol. Dis. 13:177-190, 2003.259Yoritaka et al., "Immunohistochemical Detection of 4-Hydroxynonenal Protein Adducts in Parkinson Disease," Proc. Natl. Acad. Sci. U.S.A. 93:2696-2701, 1996.260Yoshikai et al., "Genomic Organization of the Human Amyloid Beta-protein Precursor Gene," Gene 87:257-263, 1990.Referenced byCiting PatentFiling datePublication dateApplicantTitleUS8409575Aug 26, 2011Apr 2, 2013Bioarctic Neuroscience AbAntibodies specific for amyloid beta protofibrilUS8632776Feb 25, 2011Jan 21, 2014Bioarctic Neuroscience AbProtofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other α-synucleinopathiesClassifications U.S. Classification530/324, 424/198.1, 530/300, 424/185.1, 424/184.1International ClassificationA01K67/027, C12N15/09, A61K45/00, G01N33/15, C07K16/18, A61K39/395, G01N37/00, A61P37/04, C12N5/10, G01N33/50, C12N1/15, C12N1/21, C12N1/19, A61P25/28, A61K39/38, C07K14/47, A61K39/00, C07K17/00, C07K5/00, C07K16/00, A61K38/00Cooperative ClassificationA61K38/00, A61K2039/505, C07K14/4711European ClassificationC07K14/47A3Legal EventsDateCodeEventDescriptionSep 27, 2013FPAYFee paymentYear of fee payment: 4Jun 29, 2007ASAssignmentOwner name: BIOARCTIC NEUROSCIENCE AB, SWEDENFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANNFELT, LARS;NILSBERTH, CAMILLA;CAMPBELL, ANITA;AND OTHERS;REEL/FRAME:019499/0017;SIGNING DATES FROM 20040501 TO 20070516Owner name: BIOARCTIC NEUROSCIENCE AB,SWEDENFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANNFELT, LARS;NILSBERTH, CAMILLA;CAMPBELL, ANITA AND OTHERS;SIGNED BETWEEN 20040501 AND 20070516;US-ASSIGNMENT DATABASE UPDATED:20100420;REEL/FRAME:19499/17Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANNFELT, LARS;NILSBERTH, CAMILLA;CAMPBELL, ANITA;AND OTHERS;SIGNING DATES FROM 20040501 TO 20070516;REEL/FRAME:019499/0017RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google